- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07950358
A Single-Center, Randomized Controlled Trial of Transcoronary Radiofrequency Ablation Versus Transcoronary Alcohol Ablation for Hypertrophic Obstructive Cardiomyopathy
Patients with hypertrophic obstructive cardiomyopathy (HOCM) require septal reduction therapy to relieve left ventricular outflow tract obstruction (LVOTO). Septal myectomy is an open surgical procedure that resects hypertrophied septal myocardium to reduce outflow tract obstruction. However, it is associated with relatively substantial trauma. Some patients cannot tolerate surgery due to comorbidities or decline open-chest surgery.
Transcoronary alcohol ablation is a classic minimally invasive septal reduction therapy with a clinical history of nearly 30 years. Alcohol ablation induces myocardial injury via a chemical agent to reduce septal hypertrophy, widen the left ventricular outflow tract, lower the systolic pressure gradient, and improve clinical symptoms. It serves as a minimally invasive alternative to surgery. Nevertheless, the efficacy of this technique is highly dependent on the anatomical features of septal branches. Suboptimal outcomes may occur in some patients owing to variable septal branch anatomy. In addition, due to the high myocardial permeability of alcohol, atrioventricular block occurs in approximately 20% of patients after the procedure.
In recent years, transcoronary radiofrequency ablation has emerged as a novel minimally invasive septal reduction approach in clinical practice. For radiofrequency ablation, a microcatheter is advanced over a coronary guidewire into the septal branch. The proximal end of the guidewire is connected to a radiofrequency ablation generator, and myocardial ablation is delivered around the guidewire tip. Occlusion of the septal branch may further potentiate the ablative effect. This technique is less limited by anatomical variations of septal branches, features a shorter learning curve, and may have less impact on the conduction system. Compared with alcohol ablation, it enables more precise ablation with potentially superior safety. Both minimally invasive strategies achieve an obstruction relief rate exceeding 90%. To date, head-to-head data comparing the efficacy and safety profiles of these two minimally invasive therapies remain absent. Therefore, this randomized controlled trial is designed to compare the efficacy and safety of transcoronary alcohol ablation versus transcoronary radiofrequency ablation for hypertrophic obstructive cardiomyopathy.
You will be randomized in a 1:1 ratio to either the transcoronary alcohol ablation group or the transcoronary radiofrequency ablation group using a block randomization schedule. The probability of assignment to either group is 50%.
After randomization, cardiopulmonary exercise testing data, laboratory results and echocardiographic data will be collected at baseline, and the impact of cardiomyopathy on your quality of life will be assessed. Procedures in both groups will be performed by designated operators of the study team following standardized protocols. You will be blinded to the assigned treatment. In both groups, SonoVue will be injected into the coronary septal branch intraoperatively, and transthoracic echocardiography will be used to confirm that the ablation target is the critical site responsible for obstruction to ensure precise treatment. In the alcohol ablation group, 2-3 mL of absolute alcohol will be injected into the septal branch. In the radiofrequency ablation group, the guidewire will be connected to the radiofrequency generator; ablation energy will be set at 30-40 W, with 3 ablation applications of 30 seconds each at a single target site. Intraoperative electrocardiogram, heart rate, blood pressure and symptoms will be closely monitored, and the pressure gradient will be measured in real time using catheters and ultrasound. All patients will receive standardized medical therapy after the procedure. You will attend an outpatient follow-up visit at 3 months post-procedure, where repeat cardiopulmonary exercise testing, laboratory tests and echocardiography will be performed, and the post-procedure impact of cardiomyopathy on your quality of life will be re-evaluated. The primary endpoint of this study is the improvement in peak oxygen consumption on cardiopulmonary exercise testing at 3 months after treatment. No blood or tissue samples will be collected or stored for this study.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100037
- Recrutamento
- Fuwai Hospital, Chinese Academy of Medical Sciences
-
Contato:
- Ethics committee office
- Número de telefone: 010-88396282
- E-mail: fuwailunli@fuwai.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- 1. Age > 18 years; 2. Diagnosis of hypertrophic obstructive cardiomyopathy (HOCM), with resting LVOTG > 50 mmHg measured by echocardiography or cardiac catheterization; 3. Persistent symptoms despite treatment with maximally tolerated doses of beta-blockers or calcium channel blockers (CCBs); 4. New York Heart Association (NYHA) functional class II or higher; 5. Echocardiographic confirmation that the obstruction originates from the interventricular septum at the left ventricular outflow tract; 6. Suitable septal branch visualized on coronary angiography, with contrast echocardiography confirming its perfusion territory corresponds to the target ablation site; 7. Interventricular septal thickness < 30 mm; 8. High surgical risk or explicit patient refusal of septal myectomy; 9. Ability to understand the study purpose, voluntary participation, and provision of written informed consent.
Exclusion Criteria:
- Patients with severe mitral regurgitation secondary to organic mitral valve disease or other cardiac structural abnormalities requiring surgical intervention; Patients with significant stenosis of the left anterior descending coronary artery requiring percutaneous coronary intervention; Patients with bradyarrhythmia who have an indication for permanent pacemaker implantation; Patients with prior history of septal reduction therapy; Patients receiving myosin inhibitor therapy; Patients with severe hepatic or renal dysfunction; Patients with contraindications to coronary angiography and percutaneous interventional procedures; Patients with severe heart failure or cardiogenic shock who cannot maintain a supine position; Patients with a history of anaphylactic shock induced by contrast media; Patients considered ineligible for enrollment for other reasons at the investigator's discretion; Patients with pre-existing complete left bundle branch block at baseline.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: transcoronary radiofrequency ablation
Both groups received SonoVue injection into the septal branch, and transthoracic echocardiography was used to confirm that the ablation site was the critical lesion responsible for obstruction. In the TCRFA group, a microcatheter was advanced over a coronary guidewire into the septal branch; the proximal end of the guidewire was connected to a radiofrequency ablation generator, and myocardial ablation was delivered around the guidewire tip. The ablation power was set at 30-40 W, with three applications of 30 seconds each at a single target site. Intraoperatively, electrocardiogram, heart rate, blood pressure and symptoms were closely monitored in both groups, and the left ventricular outflow tract gradient (LVOTG) was measured in real time via catheter and ultrasound. For patients in the TCRFA group whose post-treatment LVOTG failed to meet the criteria for obstruction relief, supplementary endocardial ablation would be performed intraoperatively to achieve the target reduction of LVO |
Both groups received SonoVue injection into the septal branch, and transthoracic echocardiography was used to confirm that the ablation site was the critical lesion responsible for obstruction. In the TCRFA group, a microcatheter was advanced over a coronary guidewire into the septal branch; the proximal end of the guidewire was connected to a radiofrequency ablation generator, and myocardial ablation was delivered around the guidewire tip. The ablation power was set at 30-40 W, with three applications of 30 seconds each at a single target site. Intraoperatively, electrocardiogram, heart rate, blood pressure and symptoms were closely monitored in both groups, and the left ventricular outflow tract gradient (LVOTG) was measured in real time via catheter and ultrasound. For patients in the TCRFA group whose post-treatment LVOTG failed to meet the criteria for obstruction relief, supplementary endocardial ablation would be performed intraoperatively to achieve the target reduction of LVOT
Outros nomes:
|
|
Comparador Ativo: transcoronary alcohol ablation
SonoVue is injected into the septal branch, and transthoracic echocardiography is used to confirm that the ablation site is the critical site causing obstruction. In the ASA group, 2-3 mL of absolute alcohol is injected into the septal branch. Intraoperatively, the patient's electrocardiogram, heart rate, blood pressure and symptoms are closely monitored, and LVOTG is measured in real time using catheters and ultrasound. |
SonoVue is injected into the septal branch, and transthoracic echocardiography is used to confirm that the ablation site is the critical site causing obstruction. In the ASA group, 2-3 mL of absolute alcohol is injected into the septal branch. Intraoperatively, the patient's electrocardiogram, heart rate, blood pressure and symptoms are closely monitored, and LVOTG is measured in real time using catheters and ultrasound.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
absolute improvement in peak VO₂
Prazo: baseline,3 months
|
Cardiopulmonary exercise testing is performed at baseline and at 3 months after the procedure to measure peak VO₂. The absolute improvement in peak VO₂ is defined as the post-procedure value minus the baseline value. |
baseline,3 months
|
|
ncidence of new-onset complete left or right bundle branch block and/or permanent pacemaker implantation
Prazo: baseline,3 months
|
The incidence of new-onset complete left bundle branch block, complete right bundle branch block, and/or permanent pacemaker implantation occurring from the time of the index procedure up to the 3-month post-procedure follow-up. |
baseline,3 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Intraprocedural immediate reduction of LVOTG meeting criteria for obstruction relief
Prazo: Intraoperatively
|
Proportion of participants with immediate intraprocedural LVOTG reduction that satisfies the predefined criteria for relief of left ventricular outflow tract obstruction. |
Intraoperatively
|
|
Response rate of peak VO₂ at 3 months post-procedure
Prazo: Baseline and 3 months after the procedure
|
Response rate is defined as the proportion of participants achieving a predefined improvement in peak VO₂ measured by cardiopulmonary exercise testing at 3 months post-procedure versus baseline. |
Baseline and 3 months after the procedure
|
|
Reduction of LVOTG meeting obstruction relief criteria at 3 months post-procedure
Prazo: Baseline and 3 months after the procedure
|
Proportion of participants whose LVOTG reduction meets the predefined obstruction relief criteria at 3-month follow-up. |
Baseline and 3 months after the procedure
|
|
Absolute reduction of basal septal thickness
Prazo: Baseline and 3 months after the procedure
|
Absolute difference in basal interventricular septal thickness between baseline and 3 months post-procedure, assessed by echocardiography. |
Baseline and 3 months after the procedure
|
|
6-minute walk test distance
Prazo: Baseline and 3 months after the procedure
|
Distance covered during the 6-minute walk test at baseline and at 3 months post-procedure. |
Baseline and 3 months after the procedure
|
|
Canadian Cardiovascular Society (CCS) Angina Grade
Prazo: Baseline and 3 months after the procedure
|
Change in Canadian Cardiovascular Society angina grade from baseline to 3 months post-procedure. |
Baseline and 3 months after the procedure
|
|
Quality of life score
Prazo: Baseline and 3 months after the procedure
|
Change in generic quality-of-life score from baseline to 3 months post-procedure. |
Baseline and 3 months after the procedure
|
|
Kansas City Cardiomyopathy Questionnaire (KCCQ) score
Prazo: Baseline and 3 months after the procedure
|
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score from baseline to 3 months post-procedure. |
Baseline and 3 months after the procedure
|
|
Improvement in New York Heart Association (NYHA) functional class
Prazo: Baseline and 3 months after the procedure
|
Proportion of participants with improvement in New York Heart Association functional class at 3 months post-procedure compared with baseline. |
Baseline and 3 months after the procedure
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doença da Valva Aórtica
- Doenças cardiovasculares
- Doenças cardíacas
- Doenças das válvulas cardíacas
- Cardiomiopatias
- Estenose Aórtica Subvalvular
- Estenose da Válvula Aórtica
- Cardiomiopatia Hipertrófica
- Produtos químicos orgânicos
- Hidrocarbonetos
- Hidrocarbonetos, cíclicos
- Hidrocarbonetos, aromáticos
- Fenóis
- Derivados de benzeno
- Álcoons
- Salicilatos
- Hidroxibenzoatos
- Aspirina
- Etanol
Outros números de identificação do estudo
- 2025-2753
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data will not be shared to ensure patient confidentiality and comply with local institutional data protection policies.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .